Specialist in | HCG Oncology

Introduction

Dr. Vishal Kulkarni is a highly experienced medical oncologist with over 10 years of experience in the field of immunotherapy. With a certification in Pain and Palliative Care Management by IAPC and Management of Diabetes by Cleveland Clinic, USA, Dr. Vishal offers comprehensive medical care backed by his experience and expertise. He believes in taking an individualised approach to care, meeting each patient's unique needs.

Area of Expertise

Dr. Vishal Kulkarni has got an overall experience of more than 10 years and has worked and trained at some of the most reputed hospitals in India.
He has done significant work in the field of immunotherapy. He has also been part of about 60 bone marrow transplants including autologous and allogeneic transplants.
He has administered immunotherapy in more than 500 patients and is well-versed in managing the unique side effect profile of these agents. He is also interested in clinical research and teaching.
Dr. Vishal has handled over 5000 cases so far.

Research & Publications

Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report (2019). Indian Journal of Medical and Paediatric Oncology, 40(S 01), S133-S135.
Correlation of ABO Blood Group And Aphthous Ulcers-An Epidemiological Study (2015). Journal of Advanced Medical and Dental Sciences Research, 3(4), 9.
Role of haematological profile in oral submucous fibrosis: a clinical study (2015). Journal of Advanced Medical and Dental Sciences Research, 3(4), 6.
Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-centre experience (2020). Indian Journal of Medical and Paediatric Oncology, 41(01), 23-28.
Correlation Of Regorafenib With Kras And Kdr Gene Mutation In Patients With Chemotherapy Refractory Metastatic Colorectal Cancer”-asco Abstract#188288 June 2-6 2017.
Prospective Analysis Of Patients Treated With Chemotherapy In Metastatic Adenocarcinoma Of Lung—single Centre Experience- Scirp An Academic Publisher.
Correlation Of Grade Iii/Iv Gi Toxicity And Neutropenia In Patients Receiving 5fu Based Chemotherapy Regimen With Dpd Deficiency”- Asco Abstract #189020 June 2-6, 2017.
Safety and Efficacy of Neoadjuvant DOF Chemotherapy Regimen in patients with locally advanced gastro-esophageal junction cancers- A single center experience from India- journal of cancer therapy 2020,01,11(05):237-250.